Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Bioventix ( (GB:BVXP) ) just unveiled an announcement.
Bioventix reported a modest dip in interim revenue to £6.16m and profit before tax to £4.85m for the six months to 31 December 2025, while maintaining a strong cash position of £5.3m and holding its interim dividend at 70p per share. The mature vitamin D and core antibody franchises were broadly stable, with some pressure from challenging conditions in China and no immediate royalty uplift yet from Siemens’ expanded troponin assay label claim.
The standout growth driver was neurology, where Tau and neuro-related royalties rose five-fold to £150,000, reflecting expanding use of Bioventix sheep monoclonal antibodies in research-use-only blood assays for Alzheimer’s disease across major IVD groups and high-sensitivity platform companies. Management highlighted a growing pipeline around amyloid and Tau biomarkers, including work on Tau tangle pathology with the University of Gothenburg and projects in peripheral neuropathies and vascular dementia, alongside a progressing water-quality lateral flow project, reinforcing confidence that neuro-assay partnerships will translate into significant future commercial revenues and support the company’s long-term positioning in next-generation diagnostics.
The most recent analyst rating on (GB:BVXP) stock is a Buy with a £1519.00 price target. To see the full list of analyst forecasts on Bioventix stock, see the GB:BVXP Stock Forecast page.
Spark’s Take on BVXP Stock
According to Spark, TipRanks’ AI Analyst, BVXP is a Outperform.
The score is driven primarily by very strong financial quality (high profitability, strong cash conversion, and no debt). This is tempered by weak technicals (price below key moving averages with negative MACD) and signs of slowing operating momentum in 2025. Valuation and dividend yield are supportive, while corporate updates are mixed (insider buying versus revenue/profit pressure).
To see Spark’s full report on BVXP stock, click here.
More about Bioventix
Bioventix plc is a UK-based specialist in high-affinity monoclonal antibodies for clinical diagnostics, particularly automated immunoassays used in blood testing. Its sheep-derived antibodies target low-concentration biomarkers where conventional reagents are insufficient and are supplied to most major multinational diagnostics companies for applications including heart disease, neurological disorders, cancer, fertility, thyroid function and drug abuse. The group is headquartered in Farnham and listed on AIM under the ticker BVXP.
Average Trading Volume: 8,032
Technical Sentiment Signal: Sell
Current Market Cap: £71.84M
Find detailed analytics on BVXP stock on TipRanks’ Stock Analysis page.